Coronary artery disease remains the leading
|
|
- Ethan Mervyn Carter
- 5 years ago
- Views:
Transcription
1 UNMET NEEDS IN THE TREATMENT OF ATHEROSCLEROSIS: WHY ARE WE NOT DONE YET? * Evan A. Stein, MD, PhD ABSTRACT Heart disease remains the leading cause of death in the United States. Despite advances in surgical, interventional, and pharmacologic therapies for heart disease, prevention remains paramount in reducing morbidity and mortality. Almost 15 years of clinical experience with statin-based lipid-lowering therapy, including data from multiple large, evidence-based clinical trials, has brought about major changes in the approach to prevention of coronary heart disease. However, even with the gains of effective lipid-lowering therapy, a majority of at-risk individuals continue to experience clinical events, even with treatment. Statin trials have provided a strong basis for prevention of coronary disease and associated events; however, it is time to take the next step toward eradication of the disease. A number of approaches are being evaluated, such as intensified reduction of low-density lipoprotein cholesterol and increasing levels of high-density lipoprotein cholesterol. Combination lipid-lowering therapy, using existing agents or a combination of existing and new drugs, represents one promising approach to coronary risk reduction. Combination therapy offers the opportunity to explore new and emerging treatments in the reduction of coronary risk, including inflammation. (Adv Stud Med. 2003;3(4C):S306-S310) *This article is based on a presentation given by Dr Stein at a satellite symposium held during the 75th Annual Scientific Sessions of the American Heart Association. Director, Metabolic and Atherosclerosis Research Center, Cincinnati, Ohio. Address correspondence to Evan Stein, MD, Director, the Metabolic and Atherosclerosis Research Center, 3131 Harvey Ave, Suite 201, Cincinnati, OH esteinmrl@aol.com Coronary artery disease remains the leading cause of death among men and women in the United States. Approximately 14 million Americans have a history of myocardial infarction (MI) or angina. Each year, 1.1 million people have MIs; one third of these patients die from the MI, and one fourth of these patients will die within 1 hour of experiencing the MI. Thus, almost half of all coronary heart disease (CHD) deaths occur outside of a hospital, emphasizing that prevention of a first or repeated CHD event represents the best option for managing coronary disease risk. Among men, mortality from CHD decreased steadily from the mid- 1980s to the mid-1990s, but has since begun to increase. There has also been a relative increase in CHD in women, such that morbidity and mortality from CHD is approaching that of males. 1 The continuing morbidity and mortality trends clearly indicate a need for further improvement in strategies to reduce CHD risk. However, results of large, randomized, placebo-controlled trials of lipid-lowering therapy on CHD have provided the evidence base and should lead to the alteration of clinical practice that will contribute to substantial reductions in CHD mortality. The following discussion reviews the progress to date, the challenges of the future, and the potential strategies and options in lipid management to prevent CHD events. WHAT HAS BEEN ACHIEVED? Beginning with the Scandinavian Simvastatin Survival Study (4S) in 1994, results of 6 major clinical trials of various statin-based lipid-lowering therapy have now reported consistent and powerful evidence in over people that low-density lipoprotein S306 Vol. 3 (4C) April 2003
2 cholesterol (LDL-C) therapy leads to a 25% to 35% reduction in the relative risk (RR) for CHD morbidity and mortality. Moreover, the trials showed consistent benefits regardless of the baseline LDL-C level. With respect to RR reduction, virtually every population studied has benefited from lowering of LDL. Collectively, results of the trials have shown that statins currently offer the most effective approach for reducing CHD 2-7 (Table 1). The benefits of statin-based lipid-lowering therapy have extended to every major subgroup of patients examined. In the 4S trial, diabetic patients, who had a substantially higher event rate compared with nondiabetic patients, reduced their future risk of CHD after receiving simvastatin therapy to that of nondiabetic patients who had not received the statin. The Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/ TexCAPS) demonstrated the benefits of treating low-risk patients with a statin. Overall, the risk in AFCAPS/ TexCAPS for a new coronary event, which averaged approximately 1% per year, was significantly reduced during 5 years of treatment with lovastatin. As in the other statin trials, the benefits of treatment emerged early, after about 6 months of follow-up. 5 Until recently, even with 5 major trials completed, the data had a few gaps that left room for controversy about the benefits of statin therapy. In particular, relatively little data existed with respect to the effects of statin therapy in women, in the elderly, and in patients with low LDL-C levels. Of the approximate patients included in the Heart Protection Study (HPS) population, roughly one fourth of the participants were women and almost half of the patients were between the ages of 65 and 80 years. 7 Almost one third of the HPS population had a baseline LDL-C level of less than 115 mg/dl. Overall, treatment with simvastatin resulted in a 24% reduction in the RR for vascular events, and the benefits were consistent in women, the elderly, and in patients who had low baseline LDL-C levels. The major clinical trials have also shown a surprising beneficial effect of cholesterol reduction on stroke risk, which was not anticipated when the trials were designed. Originally observed in unplanned post-hoc analyses of the data from 4S, the stroke reduction has since been confirmed in trials that included stroke a priori as an endpoint. The overall reduction in stroke risk has ranged between 11% and 40%, being primarily seen in secondary prevention trials. 8 WHAT MORE CAN BE ACHIEVED? Clearly, the ideal objective would be to eliminate all CHD events. In terms of lipid-lowering therapy, what magnitude would be required to achieve that goal? Based on results from the major secondary prevention trials, extrapolation shows an LDL-C of approximately 30 mg/dl might produce an event rate of zero. Extrapolation from primary prevention trials, which have involved a lower absolute risk, have indicated that an LDL-C level of approximately 50 mg/dl might result in total elimination of CHD events. Such extrapolation from clinical trial results raises 2 obvious questions: will increasingly greater reductions in LDL-C levels result in additional benefits, and is it feasible to attain those LDL-C levels? Data from the 4S trial suggest that greater reductions in LDL-C do translate into greater reductions in event rates. A comparison of patients whose LDL-C levels declined by <34% versus 34% to 44% showed a 5.6% absolute reduction in event rate and those whose LDL-C levels declined by 44% to 70% with simvastatin therapy had a further 2.3% reduction in absolute risk. 9 While these data suggest that greater reductions in LDL-C levels Table 1. Effect of Statin Therapy on CHD Clinical Events Trials Baseline On-Tx Statin Placebo LDL-C LDL-C Event* Event Trial (mg/dl) (% red.) Rate Rate RRR ARR NNT 4S (35) 19.4% 28.0% 34% 8.6% 12 LIPID (25) 12.3% 15.9% 24% 3.6% 28 CARE (32) 10.2% 13.2% 24% 3.0% 34 WOSCOPS (26) 5.3% 7.5% 29% 2.2% 46 AFCAPS (25) 3.5% 5.5% 37% 2.0% 50 *Nonfatal MI or CHD death in WOSCOPS, CARE, LIPID; nonfatal or fatal MI, unstable angina, or sudden cardiac death in AFCAPS; nonfatal MI, coronary death, or resuscitated cardiac arrest in 4S. vs placebo Reprinted with permission from Jacobson et al. Arch Intern Med. 1998;158:1977. Copyrighted American Medical Association. Advanced Studies in Medicine S307
3 do correlate with greater risk reduction, they do not provide a definitive answer. The Effects of Atorvastatin and Simvastatin on Atherosclerosis Progression (ASAP) trial also provides data on the relationship between LDL-C reduction and cardiac risk. 10 The trial compared aggressive lipidlowering and conventional lipid-lowering therapy in a population of patients with familial hypercholesterolemia (average baseline LDL-C level nearly 300 mg/dl). The patients began therapy with atorvastatin 40 mg/day or simvastatin 20 mg/day, and the starting doses were doubled after 4 weeks. The primary endpoint was change in carotid intimal-medial thickening (IMT) after 2 years of treatment, as assessed by B- mode ultrasound. Participating patients randomized to aggressive lipid-lowering therapy had an overall reduction in carotid IMT, whereas patients treated conventionally had an increase in IMT (P =.001). The ASAP investigators noted that aggressive cholesterol-lowering therapy induced regression of carotid IMT despite a mean LDL-C level of 150 mg/dl on treatment (after a 51% reduction in baseline LDL-C levels). The investigators concluded that future trials that have clinical, rather than anatomical, endpoints are necessary to demonstrate the benefits of aggressive cholesterol lowering on cardiovascular morbidity and mortality. Several ongoing trials might provide more definitive answers regarding the benefits of aggressive versus conventional cholesterol-lowering therapy. The Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) trial involves CHD patients treated with simvastatin 20 mg/day or 80 mg/day with or without folate/vitamin B 12 supplementation. Patients are being followed for 5 years, and the primary endpoints are cardiovascular death and non-fatal MI. LDL-C targets for the trial are 100 mg/dl in patients receiving 20 mg of simvastatin and 70 mg/dl in patients receiving the higher dose of the statin. The Treat to New Targets (TNT) study involves CHD patients randomized to atorvastatin 10 mg/day or 80 mg/day. The Incremental Decrease in Endpoints through Aggressive Lipid Lowering (IDEAL) trial includes 8888 patients randomized to simvastatin mg/day or to atorvastatin 80 mg/day. The follow-up and primary endpoints in both trials are the same as in the SEARCH trial, and the TNT trial has the same LDL-C goals as SEARCH. HOW CAN WE ACHIEVE MORE CHD RISK REDUCTION? How do we reach the goal of greater decreases in vascular endpoints through lipid reductions? Strategies focus first on lipid therapy, which has proven to be efficacious in multiple clinical trials conducted over the past 2 decades, and second on a broader approach of antiatherosclerotic therapy. With respect to lipid therapy, potential therapeutic lipid targets include additional lowering of LDL-C, lowering of LDL-C plus lowering of triglyceride and raising of high-density lipoprotein cholesterol (HDL- C), and lowering of triglyceride plus the raising of HDL-C. Several strategies exist for achieving greater reductions in LDL-C. Higher statin doses have already been discussed. Other options include development of more effective statins and the use of various combinations of statins and other drug classes such as bile acid sequestrants, cholesterol absorption inhibitors, niacin, or a peroxisome proliferator activated receptor (PPAR) agonist. Other possibilities for combination with a statin are in development, including bile acid transport inhibitors and microsomal triglyceride transport protein inhibitors. (Table 2) The new-generation statin, rosuvastatin, has been shown to achieve LDL-C reductions of approximately 42% with a 10-mg dose, increasing to beyond 60% with an 80-mg dose. 11 The results represent a moderate improvement over the 52% reduction that can be achieved with maximal doses of atorvastatin. Studies of combination therapy with a statin and bile acid sequestrant have shown that this achieves Table 2. Lipid Therapy: Enhanced Efficacy LDL cholesterol More effective Stating + BAS (bile acid sequestrants) Statin + CAI (cholesterol absorption inhibitors) Statin + IBAT (bile acid transport inhibitors) Stating + MTPI (microsomal triglyceride transport inhibitors) Statin + PPAR (peroxisome proliferator-activated receptor) Statin + niacin LDL + triglycerides + HDL Cholesterol Triglycerides + HDL Cholesterol LDL = low-density lipoprotein; HDL = high-density lipoprotein. S308 Vol. 3 (4C) April 2003
4 greater lipid-lowering effects compared with a higher statin dose alone. 12 Such findings demonstrate that drugs with different mechanisms of action work well when added to a statin base. A particularly promising new approach is to combine a statin with a cholesterol absorption inhibitor. For example, adding 10 mg of ezetimibe to 10 mg of simvastatin leads to an additional 15% decrease in LDL-C compared with 10 mg of simvastatin alone. 13 Furthermore, in 1 therapeutic step, the combination achieves the same results as 3 dose escalations or an 8- fold increase of simvastatin (from 10 mg to 20, 40, and 80 mg). Moreover, the combination of a low-dose statin and ezetimibe is well tolerated and avoids potential concerns about high-dose statin monotherapy (Figure). The combination of a statin and niacin has been used for years in the United States. Niacin adds a relatively modest effect to a statin s LDL-C lowering ability. The primary impact of the combination is on triglycerides and HDL-C. One small placebo-controlled clinical trial demonstrated that the combination of niacin and simvastatin reduced the RR of a clinical event by 90% in a few years, and the overall event rate fell to 3% in patients who received the combination in a secondary prevention setting. 14 The question remains as to whether we can utilize this combination in a large clinical trial and, by also lowering triglycerides and raising HDL-C combined with significant LDL-C reduction, achieve the same results. If after appropriate use of a statin to reduce LDL-C there is need to reduce triglycerides and improve HDL-C, a logical therapeutic strategy would be the combination of simvastatin with niacin. However, given the patient and physician acceptance of niacin, fibrates are more commonly used in these patients. The combination with a fibrate remains controversial, and there is no outcome evidence of the combination at all to guide clinicians as to either the added effectiveness for CHD prevention over either drug alone, or the safety of the combination. The Veterans Affairs HDL-C Intervention Trial (VA-HIT) demonstrated that a fibrate can significantly reduce the risk of acute coronary events in high-risk patients who have existing CHD. 15 On the horizon are other potential combinations that await testing in clinical trials. These include a fibrate and a cholesteryl ester transfer protein (CETP), a PPAR-alpha agonist and a CETP inhibitor, a PPAR-alpha agonist and a statin, and others. We already know that we can improve lipoprotein profiles with these agents. However, if we beautify the lipid profile, will this translate into a greater reduction in clinical events? ANTIATHEROSCLEROTIC THERAPY Several options exist for antiatherosclerotic therapy. Aspirin reduces the risk of clinical events, so the addition of aspirin to a statin should lead to additional benefits. Other agents with proven benefits for reducing clinical events include angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and betablockers. Adding 1 or more of these agents to a statin makes sense, but the additional benefits have yet to be proven, or even evaluated in some instances, in large, well-designed clinical trials. On the horizon is the possibility of combining a statin with an acyl CoA:cholesterol acyltransferase (ACAT) inhibitor, a drug that is designed to reduce lipid uptake by the macrophage but has little if any effect on plasma lipid levels. Future improvements in reducing CHD risk will be incremental. Perhaps giving patients higher doses of Figure. New Role for Combination Therapy LDL-C = low-density lipoprotein cholesterol. Advanced Studies in Medicine S309
5 statins to achieve greater reductions in LDL-C will reduce the clinical event rate, as is being tested in the SEARCH, TNT, and IDEAL trials. Once those trials are completed, attention will turn to combination therapy in the hopes of achieving even greater reductions in clinical events. A statin might be studied in combination with niacin, a cholesterol absorption inhibitor, or a newer class of drug. Not to be overlooked is the emerging potential for therapeutic agents that target inflammation, which is the next step in atherosclerosis after apparent initiation by LDL-C entering the vascular wall. Investigation into the role of inflammation has uncovered numerous potential therapeutic targets. Also not to be overlooked are the contributions of thrombosis and fibrinolysis to acute coronary events. Various clot-related targets for reducing cardiovascular morbidity and mortality already are being explored. Finally, the quest for better therapies should not obscure the progress that has been made toward reducing cardiovascular morbidity and mortality. With currently available therapies, lowering LDL-C alone can prevent 30% to 35% of coronary events. Failure to implement current knowledge into clinical practice represents one of the biggest obstacles to reductions in coronary risk. Perhaps no more than 20% of patients with CHD actually achieve the National Cholesterol Education Program LDL-C target of less than 100 mg/dl. 16 SUMMARY Heart disease remains the leading cause of death in the United States. A high proportion of these deaths occur suddenly and out of the hospital, emphasizing that prevention offers the best option for reducing cardiovascular morbidity and mortality. Existing statins have been shown to reduce the risk of coronary events by 30% to 35%. More aggressive treatment can lead to greater reductions in LDL-C, but the impact on cardiac morbidity and mortality remains to be proven. Potential strategies to achieve greater reductions in clinical event rates include high-dose statin therapy, combination therapy with a statin and other classes of lipid-lowering agents, nonstatin combinations that primarily target triglycerides and HDL-C, and antiatherosclerotic therapy that combines lipid and nonlipid therapies. REFERENCES 1. AHA Statistical Update. Dallas, Texas:AHA; Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344: Shepherd J, Cobbe SM, Ford L, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333: Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335: Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/ TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. N Engl J Med. 1998;339: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled study. Lancet. 2002;360: Crouse JR III, Byington RP, Hoen HM, Furberg CD. Reductase inhibitor monotherapy and stroke prevention. Arch Intern Med. 1997;157: Pedersen TR, Olsson AG, Faergeman O, et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation. 1998;97: Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet. 2001;357: Olsson AG, Pears J, McKellar J, Mizan J, Raza A. Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am J Cardiol. 2001;88: Schrott HG, Stein EA, Dujovne CA, et al. Enhanced lowdensity lipoprotein cholesterol reduction and cost-effectiveness by low-dose colestipol plus lovastatin combination therapy. Am J Cardiol. 1995;75: Kosoglou T, Meyer I, Musiol B, et al. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin [abstract]. Atherosclerosis. 2000;151: Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001; 345: Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341: The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000;160: S310 Vol. 3 (4C) April 2003
Medical evidence suggests that
COMBINATION THERAPY TO ACHIEVE LIPID GOALS David G. Robertson, MD* ABSTRACT Coronary heart disease (CHD) remains the leading cause of death in the United States despite recent advances in treatment and
More informationData Alert. Vascular Biology Working Group. Blunting the atherosclerotic process in patients with coronary artery disease.
1994--4 Vascular Biology Working Group www.vbwg.org c/o Medical Education Consultants, LLC 25 Sylvan Road South, Westport, CT 688 Chairman: Carl J. Pepine, MD Eminent Scholar American Heart Association
More informationHyperlipidemia: Lowering the Bar on the Lipid Limbo. Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH
Mark slides Hyperlipidemia: Lowering the Bar on the Lipid Limbo Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH Hyperlipidemia is a common problem Nearly 50% of men in the
More informationATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationSupplementary Online Content
Supplementary Online Content Navarese EP, Robinson JG, Kowalewski M, et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and
More informationThe American Diabetes Association estimates
DYSLIPIDEMIA, PREDIABETES, AND TYPE 2 DIABETES: CLINICAL IMPLICATIONS OF THE VA-HIT SUBANALYSIS Frank M. Sacks, MD* ABSTRACT The most serious and common complication in adults with diabetes is cardiovascular
More informationRaising high-density lipoprotein cholesterol: where are we now?
European Heart Journal Supplements (23) 5 (Supplement D), D17 D25 Raising high-density lipoprotein cholesterol: where are we now? Baylor College of Medicine, Houston, Texas, U.S.A. KEYWORDS Apolipoprotein;
More informationRECOGNITION OF THE METABOLIC SYNDROME
THE METABOLIC SYNDROME IN CLINICAL PRACTICE Michael H. Davidson, MD* ABSTRACT Patients with the metabolic syndrome remain at significantly elevated risk of morbidity and mortality associated with coronary
More informationNearly 62 million people in the. ... REPORTS... New Therapeutic Options in the National Cholesterol Education Program Adult Treatment Panel III
... REPORTS... New Therapeutic Options in the National Cholesterol Education Program Adult Treatment Panel III Robert L. Talbert, PharmD Abstract Coronary heart disease (CHD) is a common, costly, and undertreated
More informationThreshold Level or Not for Low-Density Lipoprotein Cholesterol
... SYMPOSIA PROCEEDINGS... Threshold Level or Not for Low-Density Lipoprotein Cholesterol Based on a debate between Philip J. Barter, MD, PhD, FRACP, and Frank M. Sacks, MD Debate Summary As drugs, such
More informationLandmark Clinical Trials.
Landmark Clinical Trials 1 Learning Objectives Discuss clinical trials and their role in lipid and lipoprotein treatment in cardiovascular prevention. Review the clinical trials of lipid-altering drug
More informationThe updated guidelines from the National
BEYOND NCEP ATP III: LESSONS LEARNED AND FUTURE DIRECTIONS * Benjamin J. Ansell, MD, FACP ABSTRACT The National Cholesterol Education Program (NCEP) Third Adult Treatment Panel (ATP III) guidelines provide
More informationThe Third Adult Treatment Panel of the PROCEEDINGS OPTIMAL TREATMENT STRATEGIES FOR PATIENTS AT RISK FOR CHD * Benjamin J. Ansell, MD, FACP ABSTRACT
OPTIMAL TREATMENT STRATEGIES FOR PATIENTS AT RISK FOR CHD * Benjamin J. Ansell, MD, FACP ABSTRACT As a result of the National Cholesterol Education Program s Third Adult Treatment Panel (NCEP ATP III)
More informationLow HDL and Diabetic Dyslipidemia
The Lowdown: Low HDL and Diabetic Dyslipidemia Patients with diabetes commonly have a low-density lipoprotein cholesterol (LDL-C) no higher than that of the general population. What treatment is warranted
More informationEzetimibe and SimvastatiN in Hypercholesterolemia EnhANces AtherosClerosis REgression (ENHANCE)
Ezetimibe and SimvastatiN in Hypercholesterolemia EnhANces AtherosClerosis REgression (ENHANCE) Thomas Dayspring, MD, FACP Clinical Assistant Professor of Medicine University of Medicine and Dentistry
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationCase Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer
Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,
More informationAttainment of Combined Optimal Lipid Values With the Use of Niacin
www.medscape.com Attainment of Combined Optimal Lipid Values With the Use of Niacin Has AIM-HIGH Closed the Book on This Debate? Tyan Thomas Clin Lipidology. 2012;7(4):389-396. Abstract and Introduction
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationJoslin Diabetes Center Advances in Diabetes and Thyroid Disease 2013 Consensus and Controversy in Diabetic Dyslipidemia
Consensus and Controversy in Diabetes and Dyslipidemia Om P. Ganda MD Director, Lipid Clinic Joslin diabetes Center Boston, MA, USA CVD Outcomes in DM vs non- DM 102 Prospective studies; 698, 782 people,
More informationComparison of Original and Generic Atorvastatin for the Treatment of Moderate Dyslipidemic Patients
Comparison of Original and Generic Atorvastatin for the Treatment of Moderate Dyslipidemic Patients Cardiology Department, Bangkok Metropolitan Medical College and Vajira Hospital, Bangkok, Thailand Abstract
More informationCoronary heart disease (CHD) has. Clearfield The National Cholesterol Education Program Adult Treatment Panel III guidelines
the osteopathic physician. The treatment approach involves therapeutic lifestyle changes with diet, exercise, and weight loss. It requires regular, careful monitoring of serum cholesterol levels. The new
More informationChanging lipid-lowering guidelines: whom to treat and how low to go
European Heart Journal Supplements (2005) 7 (Supplement A), A12 A19 doi:10.1093/eurheartj/sui003 Changing lipid-lowering guidelines: whom to treat and how low to go C.M. Ballantyne Section of Atherosclerosis,
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Cardiovascular Risk Factors
Cardiovascular Risk Factors ROB WALKER (Dunedin, New Zealand) Lipid-lowering therapy in patients with chronic kidney disease Date written: January 2005 Final submission: August 2005 Author: Rob Walker
More informationIs Lower Better for LDL or is there a Sweet Spot
Is Lower Better for LDL or is there a Sweet Spot ALAN S BROWN MD, FACC FNLA FAHA FASPC DIRECTOR, DIVISION OF CARDIOLOGY ADVOCATE LUTHERAN GENERAL HOSPITAL, PARK RIDGE, ILLINOIS DIRECTOR OF CARDIOLOGY,
More informationAndrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION
2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL
More informationAPPENDIX B: LIST OF THE SELECTED SECONDARY STUDIES
APPENDIX B: LIST OF THE SELECTED SECONDARY STUDIES Main systematic reviews secondary studies on the general effectiveness of statins in secondary cardiovascular prevention (search date: 2003-2006) NICE.
More informationCVD Risk Assessment. Lipid Management in Women: Lessons Learned. Conflict of Interest Disclosure
Lipid Management in Women: Lessons Learned Conflict of Interest Disclosure Emma A. Meagher, MD has no conflicts to disclose Emma A. Meagher, MD Associate Professor, Medicine and Pharmacology University
More informationSTATINS FOR PAD Long - term prognosis
STATINS FOR PAD Long - term prognosis Prof. Pavel Poredos, MD, PhD Department of Vascular Disease University Medical Centre Ljubljana Slovenia DECLARATION OF CONFLICT OF INTEREST No conflict of interest
More informationHYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016
HYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016 NOTHING TO DISCLOSE I, Nicole Slater, have no actual or potential conflict
More information( Diabetes mellitus, DM ) ( Hyperlipidemia ) ( Cardiovascular disease, CVD )
005 6 69-74 40 mg/dl > 50 mg/dl) (00 mg/dl < 00 mg/dl(.6 mmol/l) 30-40% < 70 mg/dl 40 mg/dl 00 9 mg/dl fibric acid derivative niacin statin fibrate statin niacin ( ) ( Diabetes mellitus,
More informationNew Features of the National Cholesterol Education Program Adult Treatment Panel III Lipid-Lowering Guidelines
Clin. Cardiol. Vol. 26 (Suppl. III), III-19 III-24 (2003) New Features of the National Cholesterol Education Program Adult Treatment Panel III Lipid-Lowering Guidelines H. BRYAN BREWER, JR, M.D. Molecular
More informationOn May 2001, the Third Adult
THE RISK OF DIABETES: CAN WE IMPACT CHD THROUGH THE ATP III CHOLESTEROL GUIDELINES? * Based on a presentation given by Steven M. Haffner, MD, MPH ABSTRACT Diabetes has been recognized among diabetologists
More informationThe new guidelines issued in PRESENTATIONS... Future Outlook: Changing Perspectives on Best Practice
... PRESENTATIONS... Future Outlook: Changing Perspectives on Best Practice Based on a presentation by Daniel J. Rader, MD Presentation Summary The guidelines recently released by the National Cholesterol
More informationCholesterol Treatment Update
Cholesterol Treatment Update Patrick E. McBride, M.D., M.P.H. Professor of Medicine, Cardiovascular Medicine Associate Director, Preventive Cardiology Program UW School of Medicine and Public Health Disclosure:
More informationIntroduction. Objective. Critical Questions Addressed
Introduction Objective To provide a strong evidence-based foundation for the treatment of cholesterol for the primary and secondary prevention of ASCVD in women and men Critical Questions Addressed CQ1:
More informationnicotinic acid 375mg, 500mg, 750mg, 1000mg modified release tablet (Niaspan ) No. (93/04) Merck
Scottish Medicines Consortium Resubmission nicotinic acid 375mg, 500mg, 750mg, 1000mg modified release tablet (Niaspan ) No. (93/04) Merck New formulation 6 January 2006 The Scottish Medicines Consortium
More informationStatins in the Treatment of Type 2 Diabetes Mellitus: A Systematic Review.
ISPUB.COM The Internet Journal of Cardiovascular Research Volume 7 Number 1 Statins in the Treatment of Type 2 Diabetes Mellitus: A Systematic Review. C ANYANWU, C NOSIRI Citation C ANYANWU, C NOSIRI.
More informationCardiovascular disease (CVD) is the
Epidemiology/Health Services/Psychosocial Research O R I G I N A L A R T I C L E Cost Effectiveness of Statin Therapy for the Primary Prevention of Major Coronary Events in Individuals With Type 2 Diabetes
More informationHow to Reduce Residual Risk in Primary Prevention
How to Reduce Residual Risk in Primary Prevention Helene Glassberg, MD Assistant Professor of Medicine Section of Cardiology Hospital of the University of Pennsylvania Philadelphia, PA USA Patients with
More informationNicole Ciffone, MS, ANP-C, AACC Clinical Lipid Specialist
1 Nicole Ciffone, MS, ANP-C, AACC Clinical Lipid Specialist New Cardiovascular Horizons Multidisciplinary Strategies for Optimal Cardiovascular Care February 7, 2015 2 Objectives After participating in
More informationReducing low-density lipoprotein cholesterol treating to target and meeting new European goals
European Heart Journal Supplements (2004) 6 (Supplement A), A12 A18 Reducing low-density lipoprotein cholesterol treating to target and meeting new European goals University of Sydney, Sydney, NSW, Australia
More informationLIST OF ABBREVIATIONS
Diabetes & Endocrinology 2005 Royal College of Physicians of Edinburgh Diabetes and lipids 1 G Marshall, 2 M Fisher 1 Research Fellow, Department of Cardiology, Glasgow Royal Infirmary, Glasgow, Scotland,
More informationPlacebo-Controlled Statin Trials
PREVENTION OF CHD WITH LIPID MANAGEMENT AND ASPIRIN: MATCHING TREATMENT TO RISK Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of
More informationJanet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode Island Cardiology Center
Primary and Secondary Prevention of Coronary Artery Disease: What is the role of non statin drugs (fenofibrates, fish oil, niacin, folate and vitamins)? Janet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode
More informationNon-Statin Lipid-Lowering Agents M Holler - Last updated: 10/2016
Drug/Class Cholestyramine (Questran) Bile acid sequestrant Generic? Lipid Effects Y/N (monotherapy) Y LDL : 9% (4 g to 8 ; 21% (16 g to 20 ; 23% to 28% (>20 HDL : 4% to 8% (16 to 24 TG : 11% to 28% (4
More informationAdvances in Lipid Management
Advances in Lipid Management Kavita Sharma, MD Assistant Professor of Medicine, Division of Cardiology Clinical Director of the Lipid Management Clinics, The Ohio State University Wexner Medical Center
More informationLipid Therapy: Statins and Beyond. Ivan Anderson, MD RIHVH Cardiology
Lipid Therapy: Statins and Beyond Ivan Anderson, MD RIHVH Cardiology Outline The cholesterol hypothesis and lipid metabolism The Guidelines 4 Groups that Benefit from Lipid therapy Initiation and monitoring
More informationThe Power of Statins: Aggressive Lipid Lowering
Clin. Cardiol. Vol. 26 (Suppl. III), III-25 III-31 (2003) The Power of Statins: Aggressive Lipid Lowering EVAN A. STEIN, M.D., PH.D. Medical Research Laboratories International, Cincinnati, Ohio, USA Address
More informationDiabetic Dyslipidemia
Diabetic Dyslipidemia Dr R V S N Sarma, M.D., (Internal Medicine), M.Sc., (Canada), Consultant Physician Cardiovascular disease (CVD) is a significant cause of illness, disability, and death among individuals
More informationUpdate on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient
Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical
More informationWhat do the guidelines say about combination therapy?
What do the guidelines say about combination therapy? Christie M. Ballantyne, MD Center for Cardiovascular Disease Prevention Methodist DeBakey Heart & Vascular Center Baylor College of Medicine Houston,
More informationStatins in the elderly : Is there a rationale?
Statins in the elderly : Is there a rationale? Pr B Boland After a communication by Dr. Manfred Gogol EAMA, Sion, June, 2006 1 RCTs with Statins Meta-Analysis, 1999 182 abstracts or research papers 29
More informationIschemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010
Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories
More informationShould we treat everybody over 60 years with a statin? Comprehensive primary prevention in practice
Should we treat everybody over 60 years with a statin? Comprehensive primary prevention in practice Pathogenesis of atherosclerosis A decades-long disease course Inflammation Selectins ICAM IL M-CSF CRP
More informationLipid Management: Beyond LDL
Lipid Management: Beyond LDL Lisa R. Tannock MD Division of Endocrinology and Molecular Medicine University of Kentucky Overview Discuss the concept of residual risk Review current evidence-based medicine
More informationModern Lipid Management:
Modern Lipid Management: New Drugs, New Targets, New Hope Kirk U. Knowlton, M.D Director of Cardiovascular Research Co Chief of Cardiology Why lower LDL C in those without evidence of CAD (primary prevention)
More informationDisclosures No relationships (not even to an employer) No off-label uses. Cholesterol Lowering Guidelines: What now?
Disclosures No relationships (not even to an employer) No off-label uses Cholesterol Lowering Guidelines: What now?, FACP 1 2 65-year-old white woman Total cholesterol 175mg/dL HDL 54 mg/dl LDL 96 mg/dl
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More informationAmerican Osteopathic College of Occupational and Preventive Medicine 2012 Mid-Year Educational Conference St. Petersburg, Florida
The 21 st Century Paradigm Shift: Prevention Rather Than Intervention for the Treatment of Stable CHD The Economic Burden of Cardiovascular Diseases Basil Margolis MD, FACC, FRCP Director, Preventive Cardiology
More informationCLINICAL OUTCOME Vs SURROGATE MARKER
CLINICAL OUTCOME Vs SURROGATE MARKER Statin Real Experience Dr. Mostafa Sherif Senior Medical Manager Pfizer Egypt & Sudan Objective Difference between Clinical outcome and surrogate marker Proper Clinical
More informationMarshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,
Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Jamaica At the end of this presentation the participant
More informationManagement of Post-transplant hyperlipidemia
Management of Post-transplant hyperlipidemia B. Gisella Carranza Leon, MD Assistant Professor of Medicine Lipid Clinic - Vanderbilt Heart and Vascular Institute Division of Diabetes, Endocrinology and
More information2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc.
2013 Cholesterol Guidelines Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc. Disclosures Speaker Gilead Sciences NHLBI Charge to the Expert Panel Evaluate higher quality
More informationSince the release of the National Cholesterol PROCEEDINGS FUTURE DIRECTIONS IN DYSLIPIDEMIA MANAGEMENT * Michael B. Clearfield, DO, FACOI ABSTRACT
FUTURE DIRECTIONS IN DYSLIPIDEMIA MANAGEMENT * Michael B. Clearfield, DO, FACOI ABSTRACT Since the National Cholesterol Education Program (NCEP) Third Adult Treatment Panel (ATP III) guidelines, 3 large
More informationCalculating RR, ARR, NNT
Calculating RR, ARR, NNT In a trial RR = Event rate (eg # of people with one stroke/ total people) in treatment group/event rate in the control group. ARR = Event rate in control group minus the event
More informationHyperlipidemia and Cardiovascular Disease. Kathmandu November 2010 Harold E. Lebovitz, MD, FACE
Hyperlipidemia and Cardiovascular Disease Kathmandu November 21 Harold E. Lebovitz, MD, FACE Diabetes and Lifetime Risk for CHD Adjusted cummula ative incidence.7.6.5 Men 67% 3%.7.6.5 Women Diabetes No
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationThe role of statins in patients with arterial hypertension
Invited review The role of statins in patients with arterial hypertension Trygve B. Tjugen 1, Sigrun Halvorsen 1, Reidar Bjørnerheim 1, Sverre E. Kjeldsen 1, 2 1University of Oslo, Department of Cardiology,
More informationEarly Clinical Development #1 REGN727: anti-pcsk9
Early Clinical Development #1 REGN727: anti-pcsk9 July 15, 2010 Neil Stahl, Ph.D. Senior Vice President Research and Development Sciences 1 Safe Harbor Statement Except for historical information, the
More information22 Is Aggressive Lipid
22 Is Aggressive Lipid Lowering the Call in Era of Prevention of CAD? Abstract: Ever since the publication of the 4S study, lipid management has been the center of preventive therapy for coronary artery
More informationPreventing Myocardial Infarction in the Young Adult in the First Place: How Do the National Cholesterol Education Panel III Guidelines Perform?
Journal of the American College of Cardiology Vol. 41, No. 9, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Inc. doi:10.1016/s0735-1097(03)00187-6
More informationCholesterol Management Roy Gandolfi, MD
Cholesterol Management 2017 Roy Gandolfi, MD Goals Interpreting cholesterol guidelines Cholesterol treatment in diabetics Statin use and side effects therapy Reporting- Comparison data among physicians
More informationAdvanced Treatment of LDL: How Low Should You Go?
Advanced Treatment of LDL: How Low Should You Go? C. Michael White, Pharm.D., FCP, FCCP Professor and Head, Pharmacy Practice, UCONN Co-Director, HOPE Collaborative Group, UCONN/Hartford Hospital Potential
More informationAdvanced Treatment of LDL: How Low Should You Go?
Advanced Treatment of LDL: How Low Should You Go? C. Michael White, Pharm.D., FCP, FCCP Professor and Head, Pharmacy Practice, UCONN Co-Director, HOPE Collaborative Group, UCONN/Hartford Hospital Potential
More informationHow to Handle Statin Intolerance in the High Risk Patient
How to Handle Statin Intolerance in the High Risk Patient Thomas D. Conley, MD FACC FSCAI Disclosures: None 1 Definition of High Risk Primary Prevention ASCVD Risk Calculator Adults >21 yrs, LDL 190 mg/dl
More informationApplicability of Cholesterol-Lowering Primary Prevention Trials to a General Population
Applicability of Cholesterol-Lowering Primary Prevention Trials to a General Population The Framingham Heart Study ORIGINAL INVESTIGATION Donald M. Lloyd-Jones, MD; Christopher J. O Donnell, MD, MPH; Ralph
More informationPlacebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
More informationHigh risk strategies for atherosclerosis
Clinica Chimica Acta 286 (1999) 31 45 High risk strategies for atherosclerosis * Paul Cullen FRCPI, Gerd Assmann FRCP Institute of Clinical Chemistry and Laboratory Medicine and Institute of Arteriosclerosis
More informationSupplementary Online Content
Supplementary Online Content Gutierrez J, Ramirez G, Rundek T, Sacco RL. Statin therapy in the prevention of recurrent cardiovascular events: a sex-based meta-analysis. Arch Intern Med. 2012;172(12):IRA120005.
More informationSimvastatin With or Without Ezetimibe in Familial Hypercholesterolemia
Simvastatin With or Without Ezetimibe in Familial Hypercholesterolemia The trial ClinicalTrials.gov number: NCT00552097 John J.P. Kastelein, MD, PhD* Department of Vascular Medicine Academic Medical Center
More informationJUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study
Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary
More informationMisperceptions still exist that cardiovascular disease is not a real problem for women.
Management of Cardiovascular Risk Factors in the Cynthia A., MD University of California, San Diego ARHP 9/19/08 Disclosures Research support Wyeth, Lilly, Organon, Novo Nordisk, Pfizer Consultant fees
More informationLDL cholesterol and cardiovascular outcomes?
LDL cholesterol and cardiovascular outcomes? Prof Kausik Ray, BSc (hons), MBChB, FRCP, MD, MPhil (Cantab), FACC, FESC Professor of Cardiovascular Disease Prevention St Georges University of London Honorary
More informationHow much do we pay for a benefit? A Descriptive Cost Analysis of the Use of Statins. The Need for a National Cost- Effectiveness Analysis
Point of View How much do we pay for a benefit? A Descriptive Cost Analysis of the Use of Statins. The Need for a National Cost- Effectiveness Analysis José Luiz da Costa Vieira, Vera Lúcia Portal, Emílio
More informationThe statin studies: from targeting hypercholesterolaemia to targeting the high-risk patient
Q J Med 2005; 98:599 614 Advance Access publication 8 July 2005 doi:10.1093/qjmed/hci093 Commentary The statin studies: from targeting hypercholesterolaemia to targeting the high-risk patient H.T. ONG
More informationEffective Treatment Options With Add-on or Combination Therapy. Christie Ballantyne (USA)
Effective Treatment Options With Add-on or Combination Therapy Christie Ballantyne (USA) Effective treatment options with add-on or combination therapy Christie M. Ballantyne, MD Center for Cardiovascular
More informationThe inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema
The inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema Dept Cardiology, Leiden University Medical Center, Leiden,
More informationCost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan Nagata-Kobayashi S, Shimbo T, Matsui K, Fukui T
Cost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan Nagata-Kobayashi S, Shimbo T, Matsui K, Fukui T Record Status This is a critical abstract of an economic evaluation
More informationControversies in Cardiac Pharmacology
Controversies in Cardiac Pharmacology Thomas D. Conley, MD FACC FSCAI Disclosures I have no relevant relationships with commercial interests to disclose. 1 Doc, do I really need to take all these medicines?
More informationESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future
ESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future Rory Collins BHF Professor of Medicine & Epidemiology Clinical Trial Service Unit & Epidemiological Studies
More informationTHE PAST DECADE HAS WITnessed
SPECIAL COMMUNICATION Clinical Goals and Performance Measures for Cholesterol Management in Secondary Prevention of Coronary Heart Disease Thomas H. Lee, MD James I. Cleeman, MD Scott M. Grundy, MD Clayton
More informationCHOLESTEROL-LOWERING THERAPHY
CHOLESTEROL-LOWERING THERAPHY TRIALS NUMBER OF PARTICIPANTS NUMBER OF WOMEN PERCENTAGE OF WOMEN MEAN AGE MEAN - (YEARS) TRIALS WITH ANALYSIS BY GENDER N, (%) 50,194 15,036 30.0% 60.8 3.2 1/ 6 (16.7%) HR
More informationDrug Class Review HMG-CoA Reductase Inhibitors (Statins) and Fixed-dose Combination Products Containing a Statin
Drug Class Review HMG-CoA Reductase Inhibitors (Statins) and Fixed-dose Combination Products Containing a Statin Final Report Update 5 November 2009 This report reviews information about the comparative
More informationLearning Objectives. Patient Case
Joseph Saseen, Pharm.D., FASHP, FCCP, BCPS Professor and Vice Chair, Department of Clinical Pharmacy University of Colorado Anschutz Medical Campus Learning Objectives Identify the 4 patient populations
More informationApproach to Dyslipidemia among diabetic patients
Approach to Dyslipidemia among diabetic patients Farzad Hadaegh, MD, Professor of Internal Medicine & Endocrinology Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences
More informationIn May 2001, the National Cholesterol. Effective Management of Patients With Dyslipidemia REPORT. Robert J. Lipsy, PharmD
REPORT Effective Management of Patients With Dyslipidemia Robert J. Lipsy, PharmD Abstract Coronary heart disease (CHD) is the leading cause of morbidity and mortality in the United States. A direct relationship
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More information